Literature DB >> 29693845

CRITICAL REVIEW OF AVAILABLE TREATMENT OPTIONS FOR TREATMENT REFRACTORY DEPRESSION AND ANXIETY - CLINICAL AND ETHICAL DILEMMAS.

Dusan Kolar, Michael V Kolar.   

Abstract

Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anxiety. Beozodiazepines are effective for anxiety symptoms, but with no sustained treatment effects. Other medication treatment options for anxiety disorders are outlined. Ketamine is usually very effective in treating maior depressive disorder but without sustained benefits. Loog-term use may pose a signiticant risk of developing tolerance and dependence. Stimulant medication augmentation for treatment-resistant depression is effective for residual symptoms of depression, but effects are usually short-lasting and it sounds mor as an artificial way of improving energy, alertness and cognitive functioning. Synthetic cannabinoids and medical marijuana are increasingly prescribed for various medical conditions. but more recently also for patients with mood and anxiety disorders. All of these treatments may raise ethical dilemmas about appropriateness of prescribing these medications and a number of questions regarding the optimal treatment for patients with treatment-resistant depression and treatment refractory anxiety disorders.

Entities:  

Mesh:

Year:  2016        PMID: 29693845     DOI: 10.2298/mpns1606171k

Source DB:  PubMed          Journal:  Med Pregl        ISSN: 0025-8105


  4 in total

Review 1.  Addictive potential of novel treatments for refractory depression and anxiety.

Authors:  Dusan Kolar
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-12       Impact factor: 2.570

Review 2.  Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases.

Authors:  Yaron Ilan
Journal:  J Pers Med       Date:  2022-08-10

3.  Synergistic antidepressant- and anxiolytic-like effects of harmaline along with cinanserin in acute restraint stress-treated mice.

Authors:  Sajedeh Mosaffa; Hanieh Ahmadi; Fatemeh Khakpai; Mohaddeseh Ebrahimi-Ghiri; Mohammad-Reza Zarrindast
Journal:  Psychopharmacology (Berl)       Date:  2020-11-14       Impact factor: 4.530

4.  The associations of CNR1 SNPs and haplotypes with vulnerability and treatment response phenotypes in Han Chinese with major depressive disorder: A case-control association study.

Authors:  Chenghao Yang; Ilja M Nolte; Yanyan Ma; Xuguang An; Fokko J Bosker; Jie Li
Journal:  Mol Genet Genomic Med       Date:  2021-08-06       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.